Dissertation/Thesis Abstract

Synthesis of N-Functionalized Chiral 3-Hydroxyphenylpyrrolidines and Their Evaluation as Selective D3 Receptor Ligands
by Omran, Anahid, M.S., Southern Illinois University at Edwardsville, 2017, 121; 10616167
Abstract (Summary)

Dysfunction of dopaminergic receptor signaling in the brain is a hallmark of a number of neurodegenerative pathologies. Of the five dopamine receptors, the D3 subtype has emerged as a promising target for treating neurodegenerative diseases, especially Parkinson’s disease, due to the specific distribution of this receptor in limbic and nigrostriatal brain regions known to be associated with motor functions. Not only have D 3-selective agonists shown positive effects in re-establishing control of motor activity in animals, but they also display neuroprotective activity and may be important in reducing the dyskinesia side-effect often seen with current non-selective dopaminergic therapies. Herein we report the extension of our previous studies of racemic 3-hydroxyphenyl pyrrolidines to their chiral analogues. We have used our best racemic D3 ligand, N-nonyl-3-hydroxyphenyl pyrrolidine 74 (Ki = 13 nM), as starting point. Synthesis, characterization and D3 receptor affinity of both the R- and S-enantiomer of 74 will be reported. In addition, we will describe SAR studies of new chiral N-functionalized-3-hydroxyphenylpyrrolidines (based upon the steric requirements of compound 74 in which the N-substituent has been designed to engage key residues in the secondary binding site of the D3 receptor to enhance affinity and selectivity.

Indexing (document details)
Advisor: Neumann, William L.
Commitee: Crider, Michael A., Lu, Yun
School: Southern Illinois University at Edwardsville
Department: Chemistry
School Location: United States -- Illinois
Source: MAI 57/01M(E), Masters Abstracts International
Subjects: Chemistry, Organic chemistry
Keywords: Dopamine D3, Medicinal chemistry, Parkinson's disease
Publication Number: 10616167
ISBN: 978-0-355-33645-0
Copyright © 2020 ProQuest LLC. All rights reserved. Terms and Conditions Privacy Policy Cookie Policy